Use of Colchicine and Steroids in the Treatment of Alcoholic Liver Disease

  • John T. Galambos
  • Stan P. Riepe


To date, only one group has reported its clinical experience with colchicine therapy. This study included a randomized clinical trial of 22 patients and an open study of 53 patients. The beneficial effect of 1 mg colchicine daily for five days a week has been promising but not convincing.

Corticosteroid therapy for the treatment of alcoholic hepatitis was evaluated in nine short-term randomized clinical trials that included 150 treated and 161 control patients with a mortality rate of 37 and 44%, respectively. In these studies, encephalopathy was present in 80 treated and 76 control patients with a mortality rate of 59 and 74%, respectively. None of these differences is significant. The studies did document that patients with mild disease require no specific therapy besides abstinence and general supportive measures; those with severe disease showed a trend toward better survival on corticosteroid therapy. This trend was strong in the earlier publications, but was absent in the most recent studies, which included the largest numbers of patients.


Corticosteroid Therapy Alcoholic Liver Disease Chronic Active Hepatitis Alcoholic Hepatitis Prednisolone Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Paronetto F: Immunologic factors in alcoholic liver disease. Semin Liver Dis 1:232–243, 1981.PubMedCrossRefGoogle Scholar
  2. 2.
    Tennenbaum JI, Ruppert RD, Pierre RL, et al: The effect of chronic alcohol administration on the immune responsiveness of rats. J Allerg 44:272–281, 1969.PubMedCrossRefGoogle Scholar
  3. 3.
    Leevy CM, Kanagasundaram N, Matsumoto K, et al: Alcoholic hyalin and immunologic reactivity, in Eddleston ALWF, Weber JCP, Williams R (eds): Immune Reactions in Liver Disease. Kent, England, Pitman Medical, 1979, pp 195–207.Google Scholar
  4. 4.
    Gluud C, Hardt F, Aldershvile J, et al: Isolation of Mallory bodies and an attempt to demonstrate cell mediated immunity to Mallory body isolate in patients with alcoholic liver disease. J. Clin Pathol 34:1010–1016, 1981.PubMedCrossRefGoogle Scholar
  5. 5.
    MacSween RNM: Immune responses to hyalin, in Eddieston ALWF, Weber JCP, Williams R (eds): Immune Reactions in Liver Disease. Kent, England, Pitman Medical, 1979, pp 215–217.Google Scholar
  6. 6.
    Swerdlow M, Chowdhury L, Horn T: Morphologically distinctive markers of alcoholic liver disease. Lab Invest 44:64A–65A, 1981.Google Scholar
  7. 7.
    Kanagasundaram N, Leevy CM: Immunologic aspects of liver disease. Med Clin North Am 63:631–642, 1979.PubMedGoogle Scholar
  8. 8.
    Popper H: Summary of the conference, in Gerlach U, Pott G, Rauterberg J, Voss B (eds): Connective Tissue of the Normal and Fibrotic Human Liver: Present State of Biochemistry, Clinical Evaluation and Treatment. Stuttgart, Georg Thieme Verlag, 1982, pp 246–258.Google Scholar
  9. 9.
    Zetterman RK, Sorrell MF: Immunologic aspects of alcoholic liver disease. Gastroenterology 81:616–624, 1981.PubMedGoogle Scholar
  10. 10.
    Galambos JT: Natural history of alcoholic hepatitis. III. Histological changes. Gastroenterology 63:1026–1035, 1972.PubMedGoogle Scholar
  11. 11.
    Galambos JT: Cirrhosis. Philadelphia, WB Saunders, 1979.Google Scholar
  12. 12.
    Galambos JT: Clues from clinical patterns of disease, in Eddleston ALWF, Weber JCP, Williams R (eds): Immune Reactions in Liver Disease. Kent, England, Pitman Medical, 1979, p 224.Google Scholar
  13. 13.
    Eddleston ALWF: Alcoholic liver disease: Immunology and treatment, in Proceedings of the 12th International Congress of Chemotherapy. American Society for Microbiology (in press).Google Scholar
  14. 14.
    Helman RA, Temko MH, Nye SW, et al: Alcoholic hepatitis: Natural history and evaluation of prednisolone therapy. Ann Intern Med 74:311–321, 1971.PubMedGoogle Scholar
  15. 15.
    Lesesne HR, Bozymski EM, Fallon HJ: Treatment of alcoholic hepatitis with encephalopathy: Comparison of prednisolone with caloric supplements. Gastroenterology 74:169–173, 1978.PubMedGoogle Scholar
  16. 16.
    Porter HP, Simon FR, Pope CE II, et al: Corticosteroid therapy in severe alcoholic hepatitis: A double-blind drug trial. N. Engl J Med 284:1350–1355, 1971.PubMedCrossRefGoogle Scholar
  17. 17.
    Campra JL, Hamlin EM Jr, Kirshbaum RJ, et al: Prednisone therapy of acute alcoholic hepatitis: Report of a controlled trial. Ann Intern Med 79:625–631, 1973.PubMedGoogle Scholar
  18. 18.
    Blitzer BL, Mutchnick MG, Joshi PH, et al: Adrenocorticosteroid therapy in alcoholic hepatitis: A prospective, double-blind randomized study. Am J Dig Dis 22:477–484, 1977.PubMedCrossRefGoogle Scholar
  19. 19.
    Maddrey WC, Boitnott JK, Bedine MS, et al: Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75:193–199, 1978.PubMedGoogle Scholar
  20. 20.
    Depew W, Boyer T, Omata M, et al: Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 78:524–529, 1980.PubMedGoogle Scholar
  21. 21.
    Schlichting P, Juhl E, Poulsen H, et al: Alcoholic hepatitis superimposed on cirrhosis: Clinical significance and effect of long-term prednisone treatment. Scand J Gastroenterol 11:305–312, 1976.PubMedGoogle Scholar
  22. 22.
    Shumaker JB, Resnick RH, Galambos JT, et al: A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. Am J Gastroenterol 69:443–449, 1978.PubMedGoogle Scholar
  23. 23.
    Theodossi A, Eddleston ALWF, Williams R: Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 23:75–79, 1982.PubMedCrossRefGoogle Scholar
  24. 24.
    Ehrlich HP, Bornstein P: Microtubules in transcellular movement of procollagen. Nature (London) New Biol 238:257–260, 1972.Google Scholar
  25. 25.
    Diegelmann RF, Diegelmann RF, Peterkofsky B: Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci USA 69:892–696, 1972.PubMedCrossRefGoogle Scholar
  26. 26.
    Ehrlich HP, Ross R, Bornstein P: Effects of antimicrotubular agents on the secretion of collagen: A biochemical and morphological study. J Cell Biol 62:390–405, 1974.PubMedCrossRefGoogle Scholar
  27. 27.
    Harris ED Jr, Krane SM: Effects of colchicine on collagenase in cultures of rheumatoid synovium. Arthritis Rheum 14:669–684, 1971.PubMedCrossRefGoogle Scholar
  28. 28.
    Rojkind M, Kershenobich D: Effect of colchicine on collagen, albumin and transferrin synthesis by cirrhotic rat liver slices. Biochim Biophys Acta 378:415–423, 1975.PubMedGoogle Scholar
  29. 29.
    Kershenobich D, Garcia-Tsao G, Saldana SA, et al: Relationship between blood lactic acid and serum proline in alcoholic liver cirrhosis. Gastroenterology 80:1012–1015, 1981.PubMedGoogle Scholar
  30. 30.
    Leoni S, Spagnuolo S, Conte Devirgiliis L, et al: Effect of colchicine on rat liver plasma membrane. Biochim Biophys Acta 596:451–455, 1980.PubMedCrossRefGoogle Scholar
  31. 31.
    Nicholson GK, Poste G, Ji TH: in Poste G, Nicolson GL (eds): Dynamic Aspects of Cell Surface. Amsterdam, North-Holland, 1977, pp 1–73.Google Scholar
  32. 32.
    Wallace SL, Omokoku B, Ertel NH: Colchicine plasma levels: Implications as to pharmacology and mechanism of action. Am J Med 48:443–448, 1970.PubMedCrossRefGoogle Scholar
  33. 33.
    Garcia-Tsao G, Mourelle M, Rojkind M: Colchicine improves alkaline phosphatase activity in plasma membranes of CCl4 treated rats. Gastroenterology 79:1018, 1980 (abstract).Google Scholar
  34. 34.
    Kershenobich D, Uribe M, Suarez Gl, et al: Treatment of cirrhosis with colchicine: A double blind randomized trial. Gastroenterology 77:532–536, 1979.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • John T. Galambos
    • 1
  • Stan P. Riepe
    • 1
  1. 1.Division of Digestive Diseases, Department of MedicineEmory University School of MedicineAtlantaUSA

Personalised recommendations